[
  {
    "ts": null,
    "headline": "Wound Debridement Devices Market Insights, Competitive Landscape, and Forecast Report 2025-2032 Featuring B. Braun Melsungen, Essity Aktiebolag, PAUL HARTMANN",
    "summary": "The wound debridement devices market is set to grow at a 5.53% CAGR from 2025 to 2032, reaching USD 7.66 billion. Driven by rising chronic wounds and innovation, gels lead product types. North America dominates due to a high diabetes prevalence and strong player presence. Key players include B. Braun, Smith+Nephew, and Zimmer Biomet.Dublin, July 25, 2025 (GLOBE NEWSWIRE) -- The \"Wound Debridement Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032\" has been added to Rese",
    "url": "https://finnhub.io/api/news?id=30acb759a659df09227cc135a219efedb11b12d631ff3e1789e0db6ed41e8f03",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753456320,
      "headline": "Wound Debridement Devices Market Insights, Competitive Landscape, and Forecast Report 2025-2032 Featuring B. Braun Melsungen, Essity Aktiebolag, PAUL HARTMANN",
      "id": 136089117,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZBH",
      "source": "Yahoo",
      "summary": "The wound debridement devices market is set to grow at a 5.53% CAGR from 2025 to 2032, reaching USD 7.66 billion. Driven by rising chronic wounds and innovation, gels lead product types. North America dominates due to a high diabetes prevalence and strong player presence. Key players include B. Braun, Smith+Nephew, and Zimmer Biomet.Dublin, July 25, 2025 (GLOBE NEWSWIRE) -- The \"Wound Debridement Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032\" has been added to Rese",
      "url": "https://finnhub.io/api/news?id=30acb759a659df09227cc135a219efedb11b12d631ff3e1789e0db6ed41e8f03"
    }
  },
  {
    "ts": null,
    "headline": "Can ISRG's Strong Q2 Procedure Volume Translate Into Durable EPS Upside?",
    "summary": "ISRG's Q2 procedure growth hits 17%, but continuation of EPS growth hinges on easing margin pressure from FX and da Vinci 5 adoption.",
    "url": "https://finnhub.io/api/news?id=5f96b36414fc70025ab1f83d4bbefb06902398bfc5084429114b52ac27948b48",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753447200,
      "headline": "Can ISRG's Strong Q2 Procedure Volume Translate Into Durable EPS Upside?",
      "id": 136088643,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZBH",
      "source": "Yahoo",
      "summary": "ISRG's Q2 procedure growth hits 17%, but continuation of EPS growth hinges on easing margin pressure from FX and da Vinci 5 adoption.",
      "url": "https://finnhub.io/api/news?id=5f96b36414fc70025ab1f83d4bbefb06902398bfc5084429114b52ac27948b48"
    }
  }
]